Has Astec Lifescienc declared dividend?

Astec Lifesciences Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of July 21, 2023. However, the dividend yield is 0%, and total returns over various periods show significant declines in stock price.

Astec Lifesciences Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 21 Jul 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -26.09%, the dividend return was 0%, resulting in a total return of -26.09%.<BR><BR>Over the past year, the price return was -30.47%, the dividend return was 0%, leading to a total return of -30.47%.<BR><BR>In the 2-year period, the price return was -43.16%, with a dividend return of 0.11%, culminating in a total return of -43.05%.<BR><BR>For the 3-year period, the price return was -55.72%, the dividend return was 0.17%, resulting in a total return of -55.55%.<BR><BR>In the 4-year period, the price return was -42.55%, with a dividend return of 0.33%, leading to a total return of -42.22%.<BR><BR>Over the last 5 years, the price return was 8.85%, the dividend return was 0.74%, resulting in a total return of 9.59%.<BR><BR>Overall, while Astec Lifesciences Ltd has declared a dividend, the total returns over various periods indicate significant declines in price, with only modest positive returns in the longer term. The dividend yield remains at 0%, suggesting limited income generation from dividends relative to the stock price.

Who are the peers of the Astec Lifescienc?

Astec Lifescienc's peers include P I Industries, UPL, Bayer CropSci., and others. In terms of management risk, Astec Lifescienc is rated below average, with a 1-year return of -35.47%, the lowest among its peers.

Peers: The peers of Astec Lifescienc are P I Industries, UPL, Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, Heranba Inds, Dharmaj Crop, Shivalik Rasayan, and Best Agrolife.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bayer CropSci., Dhanuka Agritech, and P I Industries, while Good management risk is found at Sumitomo Chemi., Best Agrolife, and Heranba Inds. Average management risk is present at UPL, Dharmaj Crop, and the rest. Below Average management risk is noted at Astec Lifescienc and Shivalik Rasayan. In terms of Growth, Excellent growth is seen at P I Industries, while Average growth is found at Dharmaj Crop and the rest. Below Average growth is noted at UPL, Bayer CropSci., Sumitomo Chemi., Dhanuka Agritech, Heranba Inds, Astec Lifescienc, Shivalik Rasayan, and Best Agrolife. Capital Structure ratings show Excellent at Bayer CropSci., Sumitomo Chemi., and Dhanuka Agritech, while Good is seen at Heranba Inds and Dharmaj Crop. Average capital structure is noted at Astec Lifescienc and Best Agrolife, with Below Average at UPL and Shivalik Rasayan.<BR><BR>Return Snapshot: Dhanuka Agritech has the highest 1-year return at 32.65%, while Astec Lifescienc has the lowest at -35.47%, indicating a significant negative performance compared to its peers. Additionally, peers with negative six-month returns include Astec Lifescienc, Heranba Inds, and Best Agrolife.

Who are in the management team of Astec Lifescienc?

As of March 2023, the management team of Astec Lifescienc includes Ashok V Hiremath (Director), N B Godrej (Chairman), Balram Yadav (Director), Anurag Roy (Whole Time Director & CEO), and several independent directors, among others. The team consists of a mix of directors and key executive roles.

As of March 2023, the management team of Astec Lifescienc includes the following individuals:<BR><BR>1. Ashok V Hiremath - Director<BR>2. N B Godrej - Chairman (Non-Executive)<BR>3. Balram Yadav - Director<BR>4. Vijay Kashinath Khot - Independent Director<BR>5. Brahma Nand Vyas - Independent Director<BR>6. Tejashree Pradhan - Company Secretary & Compliance Officer<BR>7. Govindan Ramakrishna Rishinaradamangalam - Independent Director<BR>8. Dhekne Vasant Nandkumar - Independent Director<BR>9. Anjali Rajesh Gupta - Independent Director<BR>10. Anurag Roy - Whole Time Director & CEO<BR>11. Burjis Godrej - Director<BR><BR>This team encompasses a mix of directors, independent directors, and key executive roles.

What does Astec Lifescienc do?

Astec Lifesciences Ltd is a small-cap company that produces agrochemicals and pharmaceutical intermediates, reporting net sales of 1,195 Cr and a net loss of 161 Cr for March 2025. The company has a market cap of INR 2,067 Cr and a debt-to-equity ratio of 2.35.

Overview:<BR>Astec Lifesciences Ltd is a producer of agrochemicals and pharmaceutical intermediates, operating within the Pesticides & Agrochemicals industry and classified as a Small Cap company.<BR><BR>History:<BR>The company was incorporated in an unspecified year and has undergone no status changes. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,195 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -161 Cr (Quarterly Results - Mar 2025)<BR>- Market cap: INR 2,067 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 40<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 2.35<BR>- Return on Equity: -57.40%<BR>- Price to Book: 8.80<BR><BR>Contact Details:<BR>Address: GodrejOne 3rd Fl Pirojshanagar, Vikhroli (E) Eastern Exp Highw Mumbai Maharashtra : 400079<BR>Tel: 91-22-25188010<BR>Email: astecinfo@godrejastec.com<BR>Website: http://www.astecls.com

Who are the top shareholders of the Astec Lifescienc?

The top shareholder of Astec Lifescienc is Godrej Agrovet Limited, with a 64.75% stake. Other shareholders include individual investors (19.62%), mutual funds (3.96%), and foreign institutional investors (0.25%), with Nippon Life India Trustee Ltd being the largest public shareholder at 2.35%.

The top shareholders of Astec Lifescienc include Godrej Agrovet Limited, which holds the largest stake at 64.75%. The company also has a diverse range of other shareholders, including individual investors who collectively own 19.62% of the shares. Additionally, mutual funds hold 3.96% across three schemes, while foreign institutional investors (FIIs) have a smaller stake of 0.25% through eight different entities. The highest public shareholder is Nippon Life India Trustee Ltd, which manages the Nippon India Small Cap Fund, holding 2.35%.

How big is Astec Lifescienc?

As of 24th July, Astec Lifesciences Ltd has a market capitalization of 2,028.00 Cr and reported net sales of 381.31 Cr with a net loss of 134.75 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Astec Lifesciences Ltd has a market capitalization of 2,028.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 381.31 Cr, while the sum of Net Profit for the same period reflects a loss of 134.75 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 234.75 Cr and Total Assets valued at 881.42 Cr.

When is the next results date for Astec Lifescienc?

Astec Lifescienc will announce its results on 29 October 2025.

Astec Lifescienc is scheduled to declare its results on 29 October 2025.

How has been the historical performance of Astec Lifescienc?

Astec Lifescienc has experienced a significant decline in net sales and profitability, with losses increasing from a profit of 89.88 crore in March 2022 to a loss of 134.71 crore in March 2025, alongside a decrease in total assets and negative cash flow from operations.

Answer:<BR>The historical performance of Astec Lifescienc shows a declining trend in net sales and profitability over the past few years, culminating in significant losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Astec Lifescienc's net sales have decreased from 676.57 crore in March 2022 to 381.30 crore in March 2025, reflecting a downward trend in revenue generation. The total operating income followed a similar pattern, dropping from 676.57 crore in March 2022 to 381.30 crore in March 2025. The company's total expenditure, excluding depreciation, peaked at 551.91 crore in March 2023 but slightly decreased to 447.51 crore in March 2025. This resulted in an operating profit (PBDIT) that fell from 164.55 crore in March 2022 to a loss of 60.58 crore in March 2025. The profit before tax also turned negative, going from a profit of 121.13 crore in March 2022 to a loss of 140.99 crore in March 2025. Consequently, the profit after tax showed a similar decline, moving from a profit of 89.88 crore in March 2022 to a loss of 134.71 crore in March 2025. The company's total assets decreased from 979.41 crore in March 2023 to 881.42 crore in March 2025, while total liabilities also decreased from 974.93 crore to 881.42 crore during the same period. Cash flow from operating activities turned negative in March 2025, indicating challenges in generating cash from core operations. Overall, Astec Lifescienc has faced significant financial difficulties, leading to substantial losses and a decline in key financial metrics over the past few years.

Are Astec Lifescienc latest results good or bad?

Astec LifeSciences' latest results are concerning, showing a net loss of ₹24.43 crores and a 25.20% drop in revenue, marking six consecutive quarters of losses. The company faces significant operational challenges and high debt levels, indicating a crisis in profitability.

Astec LifeSciences' latest results indicate a troubling performance. In the second quarter of FY26, the company reported a net loss of ₹24.43 crores, which is a significant decline of 36.64% year-on-year. Revenue also fell sharply by 25.20% to ₹73.72 crores compared to the same quarter last year. This downward trend is concerning, especially as the company has now recorded six consecutive quarters of losses, accumulating over ₹192 crores in total losses since Q2 FY24.<BR><BR>The operating margin remains negative at -9.07%, reflecting ongoing operational challenges. Additionally, the company's debt levels have surged to ₹280 crores, creating a substantial interest burden that further complicates its financial situation. With a significant decline in stock price—down 36.13% over the past year and trading well below its 52-week high—investor confidence appears to be waning.<BR><BR>Overall, the results can be characterized as bad, highlighting a crisis of profitability and operational difficulties that the company must address to stabilize its performance and regain investor trust.

Should I buy, sell or hold Astec Lifescienc?

Is Astec Lifescienc technically bullish or bearish?

As of November 21, 2025, the technical trend for Astec Lifesciences is mildly bearish with mixed signals across various indicators, suggesting caution in the current market environment.

As of 21 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish with weak strength. Key indicators include a bearish MACD on the weekly timeframe, a mildly bullish MACD on the monthly, and a mildly bearish moving average on the daily. The RSI is bearish on the weekly and shows no signal on the monthly. While the Bollinger Bands indicate bullishness on the weekly, they are mildly bearish on the monthly. The KST remains bearish across both timeframes, and Dow Theory shows mildly bullish on the weekly but mildly bearish on the monthly. Overall, the mixed signals suggest caution in the current market environment for Astec Lifescienc.

Which are the latest news on Astec Lifescienc?

Why is Astec Lifescienc falling/rising?

As of 03-Dec, Astec Lifesciences Ltd's stock price is rising to 847.65, reflecting a 6.28% increase after a trend reversal. However, the stock has significantly underperformed over the past year and has concerning financial health, indicating a weak long-term outlook.

As of 03-Dec, Astec Lifesciences Ltd's stock price is rising, currently at 847.65, reflecting a change of 50.1 or 6.28% increase. This upward movement comes after a trend reversal, as the stock has gained following five consecutive days of decline. Today, the stock outperformed its sector by 6.65%, and it reached an intraday high of Rs 868.7, indicating a significant rebound.<BR><BR>Despite this short-term rise, it is important to note that the stock has experienced considerable underperformance over longer periods. For instance, over the past year, the stock has generated a return of -22.51%, and it has consistently underperformed against the benchmark indices, including the Sensex, over the last three years. The company's financial health is concerning, with operating losses and a high Debt to EBITDA ratio of 9.40 times, indicating a low ability to service debt. Furthermore, the company has reported negative results for the last six consecutive quarters, with net sales falling by 25.20%.<BR><BR>While the current rise in stock price may be attributed to a short-term recovery and market dynamics, the underlying fundamentals suggest a weak long-term outlook for Astec Lifesciences Ltd.